Iovance Biotherapeutics (IOVA) to Post Quarterly Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.1335) per share and revenue of $87.6740 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The firm had revenue of $71.43 million during the quarter, compared to analysts’ expectations of $77.84 million. During the same quarter in the prior year, the business earned ($0.36) earnings per share. The company’s revenue was up 44.9% on a year-over-year basis. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Up 0.5%

Shares of NASDAQ:IOVA traded up $0.02 during trading on Tuesday, reaching $4.34. The stock had a trading volume of 1,640,620 shares, compared to its average volume of 15,029,889. The stock has a fifty day simple moving average of $4.31 and a two-hundred day simple moving average of $3.73. Iovance Biotherapeutics has a 52 week low of $1.76 and a 52 week high of $5.64. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -4.55 and a beta of 0.71.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds have recently made changes to their positions in the stock. Xponance LLC lifted its stake in shares of Iovance Biotherapeutics by 19.4% during the fourth quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 3,950 shares during the period. Raymond James Financial Inc. raised its holdings in Iovance Biotherapeutics by 1.4% during the 2nd quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 4,618 shares during the last quarter. Captrust Financial Advisors lifted its position in Iovance Biotherapeutics by 13.5% during the 4th quarter. Captrust Financial Advisors now owns 46,812 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 5,563 shares during the period. The Manufacturers Life Insurance Company lifted its position in Iovance Biotherapeutics by 2.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 231,443 shares of the biotechnology company’s stock valued at $637,000 after purchasing an additional 6,228 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of Iovance Biotherapeutics by 20.4% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 40,958 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 6,933 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Analysts Set New Price Targets

IOVA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.